The technical development of equipment for radiotherapy in the direction of new technics of administering highenergy radiation, such as cobalt units, linear accelerators, and betatrons, has in our opinion decisively changed the role of deep therapy, even though in radiobiological effectiveness there is no difference between 200 kV radiation and high-energy radiation. The increase of relative depth dose, the overcoming of the barrier of injurious effects to the skin, the leveling of differences in absorption in bones and soft tissues, and the reduction of lateral scattering are basic steps toward an old ideal: making the dose distribution within the patient's body conform to the actual dimension of the individual tumor. In the era of conventional or 200-kV deep therapy, despite the possibilities of the moving field, extensive areas of the body were given a fairly uniform dose in the treatment of deeply situated tumors. This dose was often kept too low for the tumor, even though it was rather strong for healthy tissue. The therapeutic effect of such irradiation was based almost entirely on the difference in radiosensitivity between tumor and normal tissue. Only with the advent of high-energy irradiation with its especially designed moving-field irradiation and wedge filters did maximal extended dosages to deep areas of the body become possible, with clear reduction of the dosage to the surrounding tissue. By "selective" dose distribution, one may now confine the radiation effect to the tumor tissue to a degree which may be decisive for therapeutic success. This selective dose distribution is satisfactory, however, only when there is satisfactory coincidence between the dimension and form of the maximum dose and those of the tumor and its local area of expansion. Successful results, moreover, depend not only upon the accurate localization of the tumor but also upon a tremendous amount of mathematical calculation of the dose distribution, which necessarily varies from case to case. In routine work such calculation cannot be handled by ordinary reckoning. It is our belief that the use of computers is inevitable today if we would fully utilize the capacity of modern high-energy equipment. Our method of dose calculation with cobalt-50 therapy by means of a digital computer was developed in the Institute for Cancer Research, Robert-Roessle Hospital, Berlin, by Richter and Schirrmeister (1–4). It does not employ fixed-field distributions, but is based on an equation originated by Pfalzner (5):